reports
- ABGSC Food & Beverage Research
- Peter Sehested
Resolutions from the annual shareholders’ meeting 2024
Resolutions from the annual shareholders’ meeting 2024 Today an ordinary shareholders’ meeting was conducted. The following resolutions were made:• Approval of the audited Annual Report for 2023• Approval of distribution of profit with payment of an ordinary dividend of DKK 2.00 or EUR 0.27 per A/B share of DKK 2 for the last four months (September 1 - December 31) of 2023. Legacy Novozymes shareholders will then have received a total pay-out of the 2023 adjusted net profit of DKK 6.20 per share, which equals an increase of 3% compared with 2022.• Approval of the Remuneration Report fo...
Korrektion til selskabsmeddelelse nr. 25 af 30. april 2024
Korrektion til selskabsmeddelelse nr. 25 af 30. april 2024 Schouw & Co. har i dag offentliggjort selskabets delårsrapport for 1. kvartal 2024. I særskilt selskabsmeddelelse forud for offentliggørelsen af delårsrapporten har selskabet meddelt de justerede forventninger til årets omsætning og EBITDA. Selskabet er blevet opmærksom på, at der i den engelske version af denne selskabsmeddelelse desværre er sket en tastefejl, idet den øvre del af omsætningsspændet fejlagtigt er noteret til 37,2 mia. kr. mod rettelig 37,3 mia. kr., som korrekt angivet i den danske version. Selskabet beklager fej...
Correction to company announcement no. 25 of 30 April 2024
Correction to company announcement no. 25 of 30 April 2024 Today, Schouw & Co. has published its interim report for the first quarter of 2024. In a separate company announcement prior to the release of the interim report, the company has announced the adjusted full-year revenue and EBITDA guidance. The company has been made aware of a typing error in the English version of this company announcement, as the upper part of the revenue range is incorrectly stated as DKK 37.2 billion instead of DKK 37.3 billion as correctly stated in the Danish version. The company regrets the error. Aktie...
- ABGSC Financials Research
- Jan Erik Gjerland
- Magnus Andersson
- Patrik Brattelius
Tryg A/S – total number of voting rights and capital
Tryg A/S – total number of voting rights and capital With reference to section 32 of the Danish Capital Markets Act (Kapitalmarkedsloven), Tryghereby publishes the company's total number of voting rights and the total share capital. After the capital decrease registered on 29 April 2024 the company's share capital was reduced by nominal DKK 92,214,355 to nominal DKK 3,081,960,545. Tryg's nominal share capital amounts to DKK 3,081,960,545 equivalent to 616.392.109 shares and 308,196,054,500 voting rights as of 30 April 2024. Attachment
Danske Bank AS: 1 director
A director at Danske Bank AS sold 6,393 shares at 203.760DKK and the significance rating of the trade was 63/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
- ABGSC Financials Research
- Albert Broock
- Jan Erik Gjerland
- Magnus Andersson
- Patrik Brattelius
DSV, 1105 - SHARE BUYBACK IN DSV A/S
DSV, 1105 - SHARE BUYBACK IN DSV A/S Company Announcement No. 1105 On 24 April 2024, we initiated a share buyback programme, as described in Company Announcement No. 1104. According to the programme, the company will in the period from 24 April 2024 until 23 July 2024 purchase own shares up to a maximum value of DKK 1,000 million, and no more than 1,700,000 shares, corresponding to 0.79% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save fo...
Delårsrapport for 1. kvartal 2024
Delårsrapport for 1. kvartal 2024 Schouw & Co. har tirsdag offentliggjort delårsrapport for 1. kvartal 2024; Koncernens omsætning i 1. kvartal 2024 blev som forventet reduceret, drevet af en kombination af lavere priser og lavere mængder. Det realiserede EBITDA blev derimod væsentligt forøget, med BioMar som den vigtigste bidragyder, ligesom cash flow fra drift blev forbedret. Hovedpunkter 7,9 mia. kr. i omsætning – en reduktion på 9%652 mio. kr. EBITDA – en vækst på 28%171 mio. kr. i pengestrøm fra drift – en forøgelse på 266 mio. kr.6,18 kr. i resultat pr. aktie – en ...
Interim report – first quarter of 2024
Interim report – first quarter of 2024 Tuesday, Schouw & Co. released its interim report for the first quarter of 2024; As expected, consolidated revenue for Q1 2024 was down on the year before, driven by a combination of lower prices and a drop in volume sales. EBITDA, on the other hand, increased strongly with BioMar as the main contributor, and cash flows from operations improved as well. Highlights DKK 7.9bn revenue – a reduction of 9%DKK 652m EBITDA – an increase of 28%DKK 171m cash flows from operations – an increase of DKK 266mDKK 6.18 earnings per share – an increas...
Interim report for the first quarter of 2024 containing inside informa...
Interim report for the first quarter of 2024 containing inside information Schouw & Co. will today be releasing its interim report for the first quarter of 2024. The interim report contains inside information, as the guidance for full-year revenue and EBITDA differs from the guidance expressed in the company’s annual report for 2023 released on 1 March 2024. The Group lowers its guidance for FY 2024 consolidated revenue to the range of DKK 34.8-37.2 billion from previously DKK 35.3-37.8 billion. At the same time, the guidance for FY 2023 consolidated EBITDA is raised to the range o...
- ABGSC Food & Beverage Research
- Peter Sehested
STEMMERETTIGHEDER OG SELSKABSKAPITAL
STEMMERETTIGHEDER OG SELSKABSKAPITAL SELSKABSMEDDELELSE nr. 33 - 30. april 2024 Efter gennemførsel af kapitalnedsættelsen meddelt 16. april 2024 er det samlede antal stemmerettigheder og den samlede kapital i DFDS A/S pr. dags dato som følger: Selskabskapital (DKK): 1.159.391.940Antal aktier: 57.969.597Antal stemmer*: 57.969.597 *hver aktie a nominelt DKK 20 giver én stemme på generalforsamlingen. Egne aktier er inkluderet i totalerne ovenfor. I henhold til kapitalmarkedslovens § 32 er DFDS A/S forpligtet til særskilt at meddele det samlede antal ste...
VOTING RIGHTS AND SHARE CAPITAL
VOTING RIGHTS AND SHARE CAPITAL COMPANY ANNOUNCEMENT no. 33 - 30 April 2024 Following the completion of the share capital reduction announced on 16 April 2024, the total number of voting rights and the total share capital in DFDS A/S as of today are as follows: Share capital (DKK): 1.159,391,940Number of shares: 57,969,597 Number of votes*: 57,969,597 * each share of nominally DKK 20 each carries one vote at the general meeting. Treasury shares are included in the numbers above. According to S. 32 of the Danish Capital Markets Act, DFDS A/S is required to sep...
Aktietilbagekøb i Spar Nord Bank – transaktioner i uge 17
Aktietilbagekøb i Spar Nord Bank – transaktioner i uge 17 Selskabsmeddelelse nr. 30 Spar Nord offentliggjorde i selskabsmeddelelse nr. 10 2024 et aktietilbagekøbsprogram på op til 500 mio. kr. Aktietilbagekøbet blev indledt 12. februar 2024. Aktietilbagekøbet sker med henblik på at nedsætte bankens aktiekapital med de under programmet købte aktier, og foretages i henhold til EU-Kommissionens forordning nr. 596/2014 af 16. april 2014 (”Markedsmisbrugsforordningen”). Under aktietilbagekøbsprogrammet er der i foregående ugegennemført følgende transaktioner: Antal akt...
Share buybacks in Spar Nord Bank – transactions in week 17
Share buybacks in Spar Nord Bank – transactions in week 17 Company announcement no. 30 In company announcement no. 10 2024, Spar Nord announced a share buyback programme of up to DKK 500 million. The share buyback was initiated on 12 February 2024. The purpose of the share buyback is to reduce the bank’s share capital by the shares acquired under the programme, and the programme is executed pursuant to Regulation (EU) No 596/2014 of 16 April 2014 (“Market Abuse Regulation”). In last week the following transactions were made under the share buyback programme. Number of sharesA...
Danske Bank A/S, ledende medarbejderes transaktioner
Danske Bank A/S, ledende medarbejderes transaktioner 30. april 2024 Indberetning nr. 44/2024 Ændring i aktiebesiddelser hos Danske Banks indberetningspligtige i henhold til EU-forordningen om markedsmisbrug I forbindelse med Danske Bank A/S’ aktietilbagekøbsprogram sælger APMH Invest A/S løbende aktier i Danske Bank A/S pro rata. For yderligere detaljer henvises til de vedhæftede skemaer, hvori transaktioner udført af personer med ledelsesansvar og personer med nær tilknytning til disse skal indberettes og offentliggøres. Kontakt: Stefan Singh Kailay, Head of Med...
Danske Bank A/S, transactions by persons discharging managerial respon...
Danske Bank A/S, transactions by persons discharging managerial responsibilities 30 April 2024 Notification no. 44/2024 Transactions made by persons obliged to report transactions to the Danish FSA and Nasdaq Copenhagen, cf. the EU Market Abuse Regulation. In connection with the share buy-back program in Danske Bank A/S, APMH Invest A/S continuously sells shares pro rata. For further details, please find the attached templates for notifications and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them. Contact: St...
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat R...
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer Company Announcement Full approval based on global Phase 3 study demonstrating overall survival benefit of TIVDAK compared to chemotherapyTIVDAK is the first antibody-drug conjugate in this patient population to have positive overall survival data COPENHAGEN, Denmark; April 30, 2024 – (Nasdaq: GMAB) and (NYSE: PFE) announced today the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TIVDAK® (tisotumab vedotin-tftv) f...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.